Tech Company Financing Transactions
Symbiotix Biotherapies Funding Round
Kairos Ventures invested in a $5 million venture round for Symbiotix Biotherapies. The round was announced by the company on 11/2/2017.
Transaction Overview
Company Name
Announced On
11/2/2017
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Kairos Ventures (James Demetriades)
Proceeds Purpose
The company will use the proceeds to advance the development of its molecular therapeutics that modulate regulatory T cell activity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 International Pl. 1400
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Overview
Symbiotix Biotherapies, Inc. is a privately-held biopharmaceutical company headquartered in Boston, Massachusetts that is developing a novel class of molecular therapeutics based on the human microbiome.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Sheila Mikhail
Chief Executive Officer
Nader Yaghoubi
Co-Founder
Dennis Kasper
Co-Founder
Lloyd Kasper
Co-Founder
Sarkis Mazmanian
VP - R & D
Shawn Hillier
Browse more venture capital transactions:
Prev: 11/2/2017: Hims venture capital transaction
Next: 11/2/2017: MariaDB venture capital transaction
Share this article
News on VC Transactions
We record all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs